Multiple vaccines: How do we choose?

被引:0
|
作者
Minkoff, Neil B. [1 ]
机构
[1] Harvard Univ, Pilgrim Hlth Care, Network Serv & Pharm, Wellesley, MA 02481 USA
来源
JOURNAL OF MANAGED CARE PHARMACY | 2007年 / 13卷 / 07期
关键词
vaccine; P&T; HPV; safety; effectiveness; cost;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: As preventive medicine is a cornerstone of managed care, most health plans have traditionally featured automatic vaccine coverage routed through the medical benefit. However, with the advent of emerging vaccines, managed care stakeholders must revise decision-making processes and choose among multiple products targeting the same disease. OBJECTIVE: To review the motivating forces behind traditional vaccine coverage in managed care and discuss the need for managed care organizations (MCOs) to subject their vaccine policies to greater examination in the changing landscape of emerging vaccines. SUMMARY: While variable vaccine coverage or choices in vaccine coverage is a relatively novel concept in managed care, the evaluation of vaccines in this setting is usually most effectively performed via a traditional route for MCOs: the Pharmacy & Therapeutics (P&T) committee. In some cases, a technology assessment committee is a more appropriate avenue for evaluation, depending on the disease state, administration, and plan infrastructure. Through these routes of evaluation, criteria similar to those used for other pharmaceutical agents under review should be employed in the review of vaccine options. The primary criteria evaluated include safety, efficacy, cost, and value. In addition, a set of miscellaneous factors must also be considered, including both tangible and intangible components. For example, the relevance of an agent to the specific covered population, compliance costs offsets, quality-of-life considerations, and both patient and provider demand should all be taken into account. Human papillomavirus vaccination provides a pragmatic example for applying the aforementioned strategy for vaccine evaluation in managed care. CONCLUSION: The changing landscape of vaccine coverage in managed care, particularly in the availability of novel agents, demonstrates a need for MCOs to subject their vaccine policies to much greater examination. Through traditional avenues such as P&T and technology assessment committees, stakeholders should seek to evaluate standard criteria such as safety, efficacy, and cost-effectiveness, with additional considerations made for factors unique to the preventive nature of vaccines.
引用
收藏
页码:S16 / S20
页数:5
相关论文
共 50 条
  • [21] HOW WE CHOOSE THE WINNERS
    HALCROW, A
    [J]. PERSONNEL JOURNAL, 1993, 72 (01) : 4 - 4
  • [22] How Do We Choose Our Giants? Perceptions of Replicability in Psychological Science
    Alister, Manikya
    Vickers-Jones, Raine
    Sewell, David K.
    Ballard, Timothy
    [J]. ADVANCES IN METHODS AND PRACTICES IN PSYCHOLOGICAL SCIENCE, 2021, 4 (02)
  • [23] How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?
    Neureiter, Daniel
    Mayr, Christian
    Kiesslich, Tobias
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 243 - 245
  • [24] Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?
    Szpisjak, Laszlo
    Salamon, Andras
    Zadori, Denes
    Klivenyi, Peter
    Vecsei, Laszlo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (01) : 1 - 4
  • [25] Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?
    Alison M. MacKenzie
    Andrew J. Peacock
    [J]. Current Hypertension Reports, 2015, 17
  • [26] How do we choose the appropriate animal model for antiseizure therapy development?
    Barker-Haliski, Melissa
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (10) : 947 - 951
  • [27] Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?
    MacKenzie, Alison M.
    Peacock, Andrew J.
    [J]. CURRENT HYPERTENSION REPORTS, 2015, 17 (07)
  • [28] How do you choose?
    Wood, ME
    [J]. PSYCHOLOGIST, 2001, 14 (10) : 514 - 515
  • [29] New vaccines - which ones should we choose?
    Robinson, Joan
    [J]. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2013, 24 (04): : 177 - 178
  • [30] How We Choose Cover Images
    Buriak, Jillian M.
    [J]. CHEMISTRY OF MATERIALS, 2015, 27 (16) : 5451 - 5452